Actinic Keratosis: Clinical Trials

186 trials for Actinic Keratosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

155 completed, 13 unknown, 7 terminated, 4 recruiting. 53 Phase 3, 48 Phase 2, 31 Phase 1, 23 Not applicable, 21 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 353Completed 46, Terminated 3, Recruiting 2, Unknown 1, Withdrawn 1
Phase 248Completed 43, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1
Phase 131Completed 29, Recruiting 1, Terminated 1
Not applicable23Completed 13, Unknown 6, Withdrawn 2, Not yet recruiting 1, Terminated 1
Phase 421Completed 16, Unknown 4, Terminated 1
Early Phase 12Completed 1, Withdrawn 1

Follow Actinic Keratosis: new trials by email Literature Review of Actinic Keratosis trials Research Report on Actinic Keratosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Therapeutic Induction of Dermal Remodeling in Veterans to Prevent Actinic Neoplasia Caused by Chronic Environmental Exposure to Ultraviolet Radiation
Microneedling, Trichloroacetic acid peel - Nonmelanoma Skin Cancer, Actinic Keratosis
Not applicableNot yet recruitingVA Office of Research and Development962026-11-012026-10-06
A Phase 2 Study of HW211026
HW211026 - Actinic Keratosis
Phase 2Not yet recruitingHubei Bio-Pharmaceutical Industrial Technological Institute Inc.802026-07-012026-07-09
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E. - Actinic Keratosis
Phase 3RecruitingSun Pharmaceutical Industries, Inc.2602025-11-292026-04-22
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle containing excipients only (VEH) without active ingredient, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E - Actinic Keratosis
Phase 3RecruitingSun Pharmaceutical Industries, Inc.1602025-11-192026-04-22
The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans
Imipramine, Control Vehicle - Actinic Keratosis, Imipramine
Phase 2RecruitingVA Office of Research and Development482025-04-012025-12-22
Trial to Investigate GZ21T in Healthy Volunteers
GZ21T - Actinic Keratosis
Phase 1CompletedGenzada Pharmaceuticals USA, Inc.412024-08-192026-01-28
Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients
Biopsy, Calcipotriene, Fluorouracil - Actinic Keratosis
Phase 2Active not recruitingUniversity of Arizona562024-07-022025-09-24
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
Bimiralisib - Actinic Keratosis
Phase 2CompletedTORQUR462024-04-022025-07-18
Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses
Topical aminolevulinate (10% ALA gel), Red light illumination - Actinic Keratosis
Phase 2CompletedCase Comprehensive Cancer Center302023-10-022025-10-23
Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face
Tirbanibulin - Actinic Keratosis
Phase 4CompletedMedical University of Graz222023-05-112023-11-14
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
Tirbanibulin 2.5 mg ointment - Actinic Keratosis
Phase 4CompletedAlmirall, S.A.3342023-01-202025-02-20
The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy
Imipramine, Vehicle - Imipramine, Photodynamic Therapy
Phase 1RecruitingWright State University242023-01-192026-08-20
MRB 0.3% Serum Effectiveness on 2 Early Clinical Markers of Photoinduced Cutaneous Aging: Actinic Lentigo and Actinic Keratosis
Topical application of MRB 0.3% serum and placebo serum (hemi face or skull) - Actinic Keratosis, Actinic Lentigo
Not applicableUnknownNAOS Institute of Life Science352022-01-012021-12-30
A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp
KX01 ointment 1%, Placebo - Actinic Keratosis
Phase 3CompletedPharmaEssentia1082021-12-212024-04-19
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
BF-200 ALA and red light LED lamp - Actinic Keratosis, Keratosis, Actinic
Phase 1CompletedBiofrontera Bioscience GmbH1122021-12-012024-10-17
Pain Management During a Photodynamic Therapy Session on the Vertex for Actinic Keratosis: Tumescent Anesthesia Interest
Procedure (Tumesent anesthesia), Control Arm (Paracetamol) - Pain, Actinic Keratosis
Not applicableUnknownPoitiers University Hospital482021-07-282021-09-29
Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States
aminolevulinic acid HCl - Actinic Keratosis, Non-melanoma Skin Cancer
Not applicableWithdrawnBrigham and Women's Hospital2020-12-012021-02-01
5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis
Solcera, Placebo, Solaraze - Actinic Keratosis
Phase 3CompletedInfectopharm Arzneimittel GmbH6312020-10-142024-03-05
Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Actinic Keratosis
Aminolevulinic acid photodynamic therapy - Actinic Keratosis
Not applicableUnknownShanghai Dermatology Hospital102020-05-012020-05-20
Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses
Photodynamic therapy (PDT), Vitamin D3 - Actinic Keratosis
Phase 2CompletedCase Comprehensive Cancer Center752020-01-132022-06-24

Showing 20 of 186. Sign in to see all of them.

Narrower conditions

Keratosis, Actinic (186)  ·  Skin Diseases (6)  ·  Carcinoma, Squamous Cell (5)  ·  Keratosis (5)  ·  Precancerous Conditions (5)  ·  Carcinoma, Basal Cell (4)  ·  Skin Neoplasms (4)  ·  Bowen's Disease (3)  ·  Melanosis (3)  ·  Warts (3)  ·  Molluscum Contagiosum (2)  ·  Rosacea (2)  ·  Tinea (2)  ·  Acne Vulgaris (1)  ·  Agnosia (1)

Broader conditions

Skin and Connective Tissue Diseases (186)  ·  Neoplasms (185)  ·  Keratosis (181)  ·  Precancerous Conditions (181)  ·  Skin Diseases (180)  ·  Neoplasms by Histologic Type (10)  ·  Carcinoma (9)  ·  Neoplasms, Glandular and Epithelial (9)  ·  Neoplasms, Squamous Cell (7)  ·  Neoplasms by Site (5)  ·  Neoplasms, Basal Cell (4)  ·  Pigmentation Disorders (4)  ·  DNA Virus Infections (3)  ·  Hyperpigmentation (3)  ·  Infections (3)

Interventions

3-ingenyl angelate (32)  ·  Aminolevulinic Acid (19)  ·  Imiquimod (16)  ·  Photochemotherapy (10)  ·  Cryotherapy (8)  ·  Fluorouracil (8)  ·  Diclofenac (7)  ·  Gels (6)  ·  Solutions (6)  ·  methyl 5-aminolevulinate (6)  ·  LEO 43204 (5)  ·  BF-200 ALA (4)  ·  Ointments (3)  ·  Cryosurgery (2)  ·  Imipramine (2)

Sponsors

LEO Pharma (29)  ·  Peplin (15)  ·  Almirall, S.A. (8)  ·  DUSA Pharmaceuticals, Inc. (6)  ·  Actavis Inc. (5)  ·  Biofrontera Bioscience GmbH (5)  ·  G&E Herbal Biotechnology Co., LTD (5)  ·  Galderma R&D (5)  ·  Sun Pharmaceutical Industries, Inc. (5)  ·  MEDA Pharma GmbH & Co. KG (4)  ·  Dong-A University (3)  ·  Graceway Pharmaceuticals, LLC (3)  ·  Icahn School of Medicine at Mount Sinai (3)  ·  The Cleveland Clinic (3)  ·  University of California, Davis (3)

Countries

United States (96)  ·  Germany (28)  ·  Australia (13)  ·  United Kingdom (8)  ·  Canada (7)  ·  Brazil (6)  ·  France (6)  ·  Italy (6)  ·  Switzerland (6)  ·  Austria (4)  ·  South Korea (4)  ·  Spain (4)  ·  Taiwan (4)  ·  Denmark (3)  ·  Netherlands (3)

Top investigators

Stuart Marcus, MD, PhD (6)  ·  C. William Hanke, MD (3)  ·  Eugene Bauer, MD (3)  ·  Daniel M Siegel, MD (2)  ·  Edward Maytin, MD, PhD (2)  ·  Gary Goldenberg, MD (2)  ·  Jane Fang, MD (2)  ·  Jonothan S Dosik, MD (2)  ·  Lars E French, MD (2)  ·  Luis A Torezan, MD (2)  ·  Rolf-Markus Szeimies, Prof Dr (2)  ·  Steve Feldman, MD, PhD (2)  ·  Alberto Lecchi (1)

Results publications

PMID 23553119, PMID 22417254, PMID 38125671, PMID 24765228, PMID 25584134, PMID 33196758, PMID 35314199, PMID 10607349, PMID 11493098, PMID 11966728, PMID 12533168, PMID 15097955, PMID 15168956, PMID 17822489, PMID 18067627, PMID 18955209, PMID 19221274, PMID 19467365, PMID 20231500, PMID 20514316, PMID 20518784, PMID 20725550, PMID 21753882, PMID 22055282, PMID 22527424, PMID 22714759, PMID 23252768, PMID 23510990, PMID 23815349, PMID 24068130, PMID 24509965, PMID 24672213, PMID 24892649, PMID 24918567, PMID 25257941, PMID 25640401, PMID 25727104, PMID 26300464, PMID 27612149, PMID 27869649, PMID 27995485, PMID 28264612, PMID 28905294, PMID 28979661, PMID 29204958, PMID 29399258, PMID 29399263, PMID 30329163, PMID 31407414, PMID 33567191

NIH funding

2014 (2), 2015 (2), 2005 (1), 2017 (1), P30CA023074 (1), R21CA156227 (1), UG1CA242596 (1)